enGene Holdings Inc. (ENGN:NASDAQ) closed at $1.58 on October 27, 2026, down 0.32% on the day. The stock trades 87.1% below its 52-week high of $12.25 and 12.5% above its 52-week low of $1.40. Over the past year, it lost 80.2%. enGene Holdings Inc. is part of the Finance sector.
In 252 trading sessions since October 24, 2025, ENGN closed higher on 118 days (47%). Its best day was November 11, 2025 (+46.76%) and its worst was May 7, 2026 (-80.56%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 1 time.
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company¿s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company¿s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
Find more stocks like ENGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.